Aarti Drugs share news, announcements and annual reports
NSE: AARTIDRUGSBSE: 524348Pharmaceuticals & BiotechnologySmall Cap
Aarti Drugs Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 1993 on BSE, Sep 2003 on NSE
Last close ₹435.20down ₹13.80 (3.07%)BSE ₹435.70
Share price at the NSE close on 30 Oct 2026. Previous close ₹449.00.
30 Oct: open ₹444.00, high ₹449.00, low ₹432.50
52-week range of traded prices to 30 Oct 2026
₹318.95Low, 30 Mar 2026₹534.00High, 10 Nov 2025
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹3,972 Cr930th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 20.78
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.56
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.46%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.37
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,91,56330.3% delivered
Aarti Drugs share news and announcements
832 announcements, routine notices left out, newest first. Page 17 of 17.
Sep 2008
8 Sep · Meeting
Aarti Drugs Ltd. has informed the Exchange regarding proceedings of the Extra Ordinary General Meeting of the Company held on September 05, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2008
28 Aug · Meeting
Aarti Drugs Ltd. has submitted to the Exchange the proceedings of the Annual General Meeting of the Shareholders of the Company held on August 23, 2008. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Aug · Meeting
Aarti Drugs Ltd. has submitted to the Exchange a copy of the Notice of the Extraordinary General Meeting of the Company scheduled to be held on September 05, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Aug · Business
Aarti Drugs Ltd. has informed the Exchange that at the meeting of the Board of Directors of the Company, held on August 6, 2008, the following decision has been taken subject to the approval of the Company at its Extra-Ordinary General Meeting to be held on September 5, 2008. Pursuant to the provisions of Section 81(1A) and all other applicable provisions of the Companies Act, 1956 ( including any statutory modifications or re-enactment thereof, for the time being in force) and pursuant to the provisions of Chapter XIII of the Securities and Exchange Board of India ( Disclosure and Investor Protection) Guidelines 2000, the Company shall issue not exceeding 6,00,000 convertible warrants, on preferential basis, to the Promoters and Promoter Group Companies, subject to the shareholder's approval, as aforesaid. Each of the said warrants would entitle the holder(s) thereof to apply for and obtain allotment of one Equity share of Rs. 10/- each thereof on a future date not exceeding 18 months from the date of allotment of warrant as per the Chapter XIII of the Securities and Exchange Board of India (Disclosure and Investors Protection) Guidelines 2000 at an issue price of Rs.52.60 ps. per share. The issue price for the warrants is fixed at 10% of the issue price of the resulting shares upon conversion. The "Relevant Date" for the purpose of determining the said issue price for the Preferential Issue of the warrants and resultant shares as aforesaid is August 6, 2008 i.e. 30 days prior to the date of the Extra-ordinary General Meeting as aforesaid at which the said preferential issue will be considered for approval in terms of Chapter XIII of the Securities and Exchange Board of India (Disclosure and Investor Protection) Guidelines 2000.1 Aug · Meeting
Aarti Drugs Ltd. has informed the Exchange that the company has announce the Book Closure from August 16, 2008 to August 23, 2008 (Both days inclusive) for the purpose of Annual General Meeting to be held on August 23, 2008 and declaration of dividend.
Jul 2008
18 Jul · Board meeting
To transact, interalia, the following business : 1) To consider and take on record the Audited Financial Results for the quarter ended June 30, 2008.
May 2008
13 May · Updates
Aarti Drugs Ltd. has submitted to the Exchange a copy of Statement of Appropriations as per clause 20 of the Listing Agreement. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 May · Dividend
Aarti Drugs Ltd. has informed the Exchange that the Board of Directors of the Company at its meeting held on May 13, 2008 has recommended Final Dividend at the rate of Rs.1.80/- (18%) per equity share of Rs.10/- each for the financial year 2007-2008.5 May · Board meeting
To transact the following business: (1) To consider and take on record the Audited Financial Results for the quarter and the year ended March 31, 2008. (2) To consider recommendation of final dividend, if any.
Apr 2008
17 Apr · Results
Aarti Drugs Ltd. has informed the Exchange that : "The Company will publish audited Financial results for the financial year 2007-08 within 3 months i.e. on or before 30th June, 2008. In view of the above the Company will not publish Unaudited Financial Results for the last quarter."9 Apr · Updates
Aarti Drugs Ltd. has informed the Exchange that: "REPAYMENT OF FCCB: The FCCB worth USD 12.75 Million issued in April 2005 has been repaid fully together with interest on due date i.e., 07th April 2008. SUCCESSFULL COMPLETION OF INSPECTION BY USFDA & EDQM: The USFDA authority has successfully completed inspection without 483 (No discrepancies) for its facilities. The company has received certification from Danish Medicine Agency, which is Regulatory Arm of EDQM, for its various manufacturing sites where company manufacture most of the molecules from its product portfolio. With the receipt of these certification, the company would be able to cater the needs of regulated market of Europe and US. The company will expect to receive better realization of the sales".
Mar 2008
31 Mar · Management
Aarti Drugs Ltd. has informed the Exchange that : "Mr. Nilesh N. Pingale, Company Secretary & Compliance Officer of the Company has resigned from the position of Company Secretary & Compliance Officer with effect from 31st March, 2008".25 Mar · Meeting
Aarti Drugs Ltd. has submitted to the Exchange a copy of the proceedings of the Extra ordinary General Meeting of the Company held on March 24, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2008
29 Feb · Meeting
Aarti Drugs Ltd. has submitted to the Exchange a copy of notice of EGM of the company to be held on 24th March,2008. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Feb · Issue of securities
Aarti Drugs Ltd. has informed the Exchange that: "At the meeting of the Board of Directors of the Company held on 22nd February, 2008, the following decision has been taken: To issue / offer securities like Foreign Currency Convertible Bonds (FCCBs) and/or Equity Shares (through Depository Receipt Mechanism) and/or Equity Shares and/or Depository Receipts (DRs) and/or any other Financial Instruments (OFIs) in foreign market or otherwise of an amount not exceeding US$ 7 Millions (US Dollars Seven Millions only) to raise funds for the purpose of the Company".
Jan 2008
28 Jan · Management
Aarti Drugs Ltd. has submitted to the Exchange the auditor's report in respect of the quarterly financial results for the quarter ended December 31, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Jan · Board meeting
To transact the following business: 1) To consider and take on record Audited Financial Results for the quarter ended December 31, 2007.
Oct 2007
18 Oct · Board meeting
To consider and take on record Audited Financial Results for the quarter and half year ended September 30, 2007.
Sep 2007
4 Sep · Meeting
Aarti Drugs Ltd. has submitted to the Exchange a copy of the proceedings of Annual General Meeting of the Company held on September 03, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2007
17 Aug · Management
Aarti Drugs Ltd. had informed the Exchange that : "Mr. Satish P. Nachane, Managing Director of the Company has resigned from the office of the Managing Director of the Company with effect from 30th July, 2007. The Resignation has been duly accepted by Board at its Meeting held on 30th July, 2007". Now the Company has clarified the Exchange that "Mr. Satish P Nachane, Managing Director of the Company has also resigned as a Director of the Company with effect from 30th July, 2007. The resignation has been duly accepted by the Board at its Meeting held on 30th July, 2007".10 Aug · Meeting
Aarti Drugs Ltd. has informed the Exchange that the company regarding the Book Closure from August 28, 2007 to September 3, 2007 (both days inclusive) for the purpose of Annual General Meeting to be held on September 3, 2007.1 Aug · Management
Aarti Drugs Ltd. has informed the Exchange that : "Mr. Satish P. Nachane, Managing Director of the Company has resigned from the office of the Managing Director of the Company with effect from 30th July, 2007. The Resignation has been duly accepted by Board at its Meeting held on 30th July, 2007".1 Aug · Management
Aarti Drugs Ltd. has informed the Exchange that : " Upon expiration of the previous tenures, the following Directors of the Company have been reappointed for a tenure of five years each w.e.f. 1st June, 2007 vide Board Resolution dated 18th May, 2007: 1) Prakash M. Patil :- Managing Director. 2) Satish P. Nachane :- Managing Director. 3) Harshit M. Savla :- Joint Managing Director. 4) Harit P. Shah :- Wholetime Director.
Jul 2007
21 Jul · Board meeting
To consider and take on record Audited Financial Results for the quarter ended June 30, 2007.3 Jul · Change in Company Secretary/Compliance Officer
Aarti Drugs Ltd. has informed the Exchange that Ms. Mona Patel, Company Secretary & Compliance Officer of the Company has resigned from the position of Company Secretary & Compliance Officer with effect from June 29, 2007. Further the Company has informed that Mr. Nilesh N. Pingale possessing requisite qualifications, has been appointed as Company Secretary & Compliance Officer of the Company with effect from June 29, 2007.
Jun 2007
15 Jun · News Verification
News Verification : The media had reports that Aarti Drugs Ltd. may merge with Aarti Industries Ltd. Further, a major drug maker may take up an equity stake in the company. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Aarti Drugs Ltd. has vide its letter inter-alia stated, "We seek to clarify that there is no such merger proposal under active consideration of the management of both the companies. Further, as regards reports on rumours of picking up equity stake by any drug major in the Company, we deny the same as baseless rumour. Nevertheless, it is further clarified that, consideration of any such merger proposal in future may not be ruled out. The Company would certainly comply with all the disclosure requirements applicable under the Listing Agreement in relation to any proposals, which will be price sensitive."
May 2007
18 May · Board meeting
Aarti Drugs Ltd. has informed the Exchange that "the Board of Directors in their meeting held on May 18, 2007 have not recommended any final dividend and the Interim dividend of Rs.1.20 ps. (12%) per share on 1,17,08,550 Equity Shares of Rs.10/- each fully paid up already declared and paid by the Company in March 2007 is confirmed as final dividend for the financial year 2006-07".7 May · Board meeting
To transact the following business: 1) To consider and take on record Audited Financial Results for the quarter and the year ended March 31, 2007. 2) To consider recommendation of final dividend, if any.
Apr 2007
24 Apr · Results
Aarti Drugs Ltd. has informed the Exchange that the Company shall publish Audited Financial Results within a period of 3 month for the year ended on March 31, 2007 i.e. on or before June 30, 2007.
Mar 2007
12 Mar · Dividend
Aarti Drugs Ltd. has informed the Exchange that: "The Board of Directors of the Company at its meeting held on Monday, 12th March, 2007 has declared 1st Interim dividend @ Rs. 1.20 ps per share (12%) for the financial year 2006-2007. The details of the dividend payable will be as under: Dividend of Rs. 1.20 ps. per share on 1,17,08,550 Equity Shares of Rs.10/- each fully paid up - Amount (Rs.) 1,40,50,260/-". Further, March 21, 2007 has been fixed as record date for the purpose of payment of 1st Interim Dividend. The aforesaid 1st Interim Dividend will be paid to registered members of the Company on or after March 23, 2007.5 Mar · Board meeting
To consider inter alia, declaration of 1st Interim dividend, if any, on the Equity Shares of the Company for the financial year ending March 31, 2007. The company has further informed the Exchange that March 21, 2007 has been fixed as the Record Date for the purpose of payment of 1st Interim Dividend on Equity Shares if any, declared. In case of approval of 1st Interim dividend by the Board of Directors, the Company shall commence despatch of dividend warrants on and from March 23, 2007.
Jan 2007
15 Jan · Board meeting
Inter-alia to consider and take on record audited financial results for the quarter ended on December 31, 2006.